(c)
a pack size containing not more than 240 doses. (S3, S4)
Flurbiprofen, when supplied by a pharmacist to a patient and intended for the treatment of posttraumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S1, S3,
S4)
Fluticasone propionate, when intended for nasal administration (other than by aerosol), in the short-term
(less than 6 months) prophylaxis and treatment of symptoms of allergic rhinitis (hay fever) in adults and
children over 12, subject to—
(a)
a maximum daily dose of 100 micrograms per nostril;
(c)
a pack size limit of 120 doses. (S3).
Formoterol.
Fusafungine.
Gadopentetic acid.
Gelsemium alkaloids; substances, preparations and mixtures thereof.
Glycopyrronium.
Halogenated hydroxyquinolines, when intended for application to the skin. (S4)
Hexametazine.
Hexoprenaline, except when contained in respirator solutions (S3) and except when intended for
injection or for the prevention or delay of labour. (S4)
Homatropine; preparations and matures thereof, except ophthalmic preparations. (S3)
Hormones (Natural or synthetic, including recombinant forms), with either hormonal or anti-hormonal
action, when intended for human vaginal use and oral contraceptives containing only progestogen and
hormones when specifically intended for emergency postcoital contraception. (S3, S4, S5)
Hydrocortisone and hydrocortisone acetate, when used in a maximum concentration of 1,0 percent in
preparations intended for application to the skin and hydrocortisone in a maximum concentration of 1,0
percent used in combination with miconazole for topical application in the treatment of athlete’s foot.
(S4)
Hydroquinone; preparations and mixtures containing 2 percent or less thereof, when intended for
application to the skin. (S3)
Hyoscine; substances, preparations and mixtures thereof, including transdermal preparations when
intended for the prevention of the symptoms of motion sickness.
Ibuprofen when used in oral medicinal preparations—
(a)
where the recommended daily dose for adults does not exceed 1,2 grams and that for
children up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body
weight;
(b)
the emergency treatment of acute gout attacks;
(c)
when intended for the treatment of post traumatic conditions such as pain, swelling
and inflammation, for a maximum period of 5 days;
except when intended for treatment of inflammatory joint disease. (S3)
Indomethacin, when intended for the emergency treatment of acute gout attacks. (S1, S3)
Iopromide.
Ipratropium bromide.
Isoaminile.
Isoprenaline (isoproterenol), except when contained in respirator solutions (S3) and except when
intended for injection. (S4)
Isopropamide.
Ketoprofen,
(a)
when intended for the short term management of headache, toothache, muscular
ache, backache, minor pain associated with arthritis, pain associated with menstrual cramps
(dysmenorrhoea), minor aches and pains associated with the common cold and fever, at a maximum
dose of 75 milligrams of ketoprofen in 24 hours;
(b)
when supplied by a pharmacist to a patient and intended for the emergency treatment
of acute gout attacks or for the treatment of post traumatic conditions such as pain, swelling and
inflammation, at a maximum dose of 100mg of ketoprofen per day, for a maximum period of 5 days. (S1,
S3)
Lansoprazole, when intended for the temporary short-term relief of heartburn and hyperacidity, subject
to—
(a)
a maximum daily dose of 15 mg
(b)
a maximum treatment period of 14 days. (S4)
Levocetirizine.
Lithium salts, when intended for application to the skin. (S5)
Lobelia alkaloids; substances, preparations and mixtures thereof.
Lodoxamide.
Loperamide
Loratadine.
Mebeverine.
Mefenamic acid, when intended for the treatment of post traumatic conditions such as pain, swelling and
inflammation, for a maximum period of 5 days; and preparations containing mefenamic acid as the only